Should S-1 be better than capecitabine for patients with advanced gastric cancer in Asia? A systematic review and meta-analysis.

S-1 or capecitabine (Cap) containing treatment is an increasingly used strategy in patients with advanced gastric cancer in Asia. It is unclear whether there is sufficient evidence to support which regimen is better.